WO1996028166A1 - Remede contre l'osteoporose et accelerateur d'osteogenese - Google Patents

Remede contre l'osteoporose et accelerateur d'osteogenese Download PDF

Info

Publication number
WO1996028166A1
WO1996028166A1 PCT/JP1995/000425 JP9500425W WO9628166A1 WO 1996028166 A1 WO1996028166 A1 WO 1996028166A1 JP 9500425 W JP9500425 W JP 9500425W WO 9628166 A1 WO9628166 A1 WO 9628166A1
Authority
WO
WIPO (PCT)
Prior art keywords
osteoporosis
bone
mepithiostan
calcium
administered
Prior art date
Application number
PCT/JP1995/000425
Other languages
English (en)
Japanese (ja)
Inventor
Kazuyoshi Iwai
Hitoshi Arita
Hisato Kakushi
Masahiro Toukin
Original Assignee
Shionogi & Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP6031798A priority Critical patent/JPH07215878A/ja
Priority claimed from JP6031798A external-priority patent/JPH07215878A/ja
Application filed by Shionogi & Co., Ltd. filed Critical Shionogi & Co., Ltd.
Priority to PCT/JP1995/000425 priority patent/WO1996028166A1/fr
Publication of WO1996028166A1 publication Critical patent/WO1996028166A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0073—Sulfur-containing hetero ring
    • C07J71/0078—Sulfur-containing hetero ring containing only sulfur
    • C07J71/0084—Episulfides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol

Definitions

  • the present invention relates to an osteogenesis promoting agent and a treatment for osteoporosis containing mepithiostan represented by the following formula (I) or ebitiostanol represented by the following formula (II) which is a metabolite thereof in the body: Agent.
  • Osteoporosis is a disease in which bone fracture or destruction occurs almost without warning due to abnormally low bone mass. Osteoporosis is the most common disease in the Japanese population, and most of it occurs in people after middle age, so it is considered to be a particular problem in the future aging society due to the prolongation of the average age. Attention has been paid.
  • Bone resorption is initiated when the surface of a quiescent bone is stimulated by a stimulant such as the hormone ⁇ a cytokine, by which unknown information is transmitted to the osteoclast by an unknown mechanism.
  • a stimulant such as the hormone ⁇ a cytokine, by which unknown information is transmitted to the osteoclast by an unknown mechanism.
  • bone formation is caused by these osteoclasts. This is done by repairing the bone that has been absorbed and broken down by osteoblasts. In a normal body, the amount of bone resorption and the amount of bone formation are in equilibrium, and this harmony in the body causes the bones to be reborn while maintaining the status quo.
  • Osteoporosis treatments are already on the market.For example, to reduce bone loss caused by low calcium intake, to increase calcium intake, for example, alphacalcidol Activated vitamin
  • the above-mentioned active vitamin D merely had the effect of efficiently ingesting calcium, and was merely a scavenging therapy for a deficiency in the amount of vitamin D consumed as food or impaired calcium absorption in the intestinal tract.
  • toxicity such as (1) calcidiaemia and (2) nephrotoxicity became a problem.
  • Calcitonin a peptide existing in the body, is known as a drug that acts to suppress the release of calcium from the osteoclasts into the blood (ie, bone resorption).
  • calcitonin derived from humans salmon calcitonin derived from salmon, as well as porcine and persimmon types are also on the market.
  • human calcitonin is difficult to purify. It is in the stage of searching for production using the biotechnology method. Studies on chimeric calcitonin, which is similar to human calcitonin, are also being conducted, but have not yet achieved any definite results.
  • calcitonin other than human calcitonin has a strong antigenicity, and has a problem that side effects such as vomiting and weight loss occur.
  • Parathyroid hormone is a biological substance secreted from the parathyroid gland due to a decrease in blood calcium concentration, and is a single-chain protein that has long been known to have the effect of increasing bone mass. Butid. However, although it increases bone mass when intermittently administered, continuous administration significantly increases bone resorption.
  • osteoporosis is viewed from bone biopsy, and high-speed osteoporosis, in which bone resorption and bone formation are actively performed, and low rotation in which bone absorption and bone formation are poor It has been found to be classified as type osteoporosis.
  • the above-mentioned PTH has an effect of increasing bone turnover and increasing bone mass, and is therefore considered to be applicable only to low-rotation osteoporosis.
  • Pyrophosphoric acid was known as a substance having a calcification-inhibiting action, but bisphosphonate derivatives obtained by replacing oxygen with a substituted carbon
  • R 1 and R J independently represent a hydroxyl group, a halogen, a substituted alkyl, a substituted amino, a octafluorothio, etc.
  • R 1 and R J independently represent a hydroxyl group, a halogen, a substituted alkyl, a substituted amino, a octafluorothio, etc.
  • vitamin K which is believed to have the effect of activating bone vitamin K-dependent protein produced from osteoblasts to suppress calcium excretion, as a therapeutic agent for osteoporosis.
  • Plant purple coconut palm Lipiflavone a synthetic derivative of the active ingredient (flavonoids) of (Alpha alpha), has also been used as an auxiliary treatment for the improvement of bone S loss, and is further administered with fluorine, vitamin D, calcium, etc. Ru attempts like mower, while £ not getting it is an effective means to fundamentally treat osteoporosis, has been pointed out for a long time for the association between hormone and osteoporosis is a biological substance. For example, it was well known that estrogen, a female hormone, has a therapeutic effect on osteoporosis. However, estrogen is known to have the side effects of abnormal irregular bleeding after menopause, and is involved in the occurrence of endometrial pain and breast cancer. ing.
  • estrogen Since estrogen has a therapeutic effect on osteoporosis, steroid hormones whose chemical structure is similar to estrogen and derivatives thereof have a therapeutic effect on osteoporosis and substances that reduce the side effects of estrogen was expected. However, practically, such research has not yet been materialized.
  • Anabolic hormones such as androgens and insulin have the effect of increasing nitrogen accumulation and promoting protein synthesis, and are thought to have the effect of increasing bone mass by suppressing the production of urinary calcium excretion. No effective osteoporosis treatment has been identified.
  • Japanese Patent Application Laid-Open No. 4-3252795 discloses that a bisphosphonate derivative having a steroid hormone as a part of its chemical structure is useful for treating bone diseases.
  • the publication does not disclose any test examples such as what kind of bone disease the compound is effective for, what specific compounds have a therapeutic effect on bone disease, and the like. Disclosure of the invention In view of the current state of the above-mentioned therapeutic agent for osteoporosis, the present inventors have attempted to create a drug having an excellent osteoporosis therapeutic action that surpasses the above-mentioned various vegetables. C The object of the present invention is here.
  • the present inventors accidentally found that mepithiostan represented by the formula (I) and ebitiostanol represented by the formula (II) have a powerful osteoporosis treatment, and completed the present invention. did.
  • the gist of the present invention resides in that at least one of mebitiostan and epitiostanol is used as an active ingredient as a therapeutic agent for osteoporosis.
  • the mepithiostan according to the present invention is a compound known as an agent for oral renal anemia and an anti-mammary tumor agent.
  • Mepithiostan exerts a hematopoietic effect by directly acting on bone ⁇ and exerts an antiestrogenic effect, thereby exhibiting a renal anemia treatment effect and a mammary tumor treatment effect.
  • Mepithiostan is metabolized in the body and is transformed into evithiosanol represented by the formula (II).
  • Mebitiostan is an orally available drug as a so-called prodrug of epipistanol, and is considered to be converted to epipistanol in vivo to exert a pharmacological action.
  • Epithiostanol is a known compound, and is used as an intramuscular injection, as well as mepithiostan, as an anti-diabetic agent and an anti-mammary tumor agent.
  • Mepithiostan and ebitiostanol are compounds that have already been marketed as drugs and have been shown to have side effects and clinically effective amounts, and are used effectively for the treatment of sexually transmitted blood and breast cancer during dialysis.
  • the present invention provides a The present invention corresponds to the second pharmaceutical use invention relating to benzophenone and epithiostanol.
  • the mepithiostan and ebitiostanol according to the present invention markedly suppressed the reduction of the calcified femoral bone weight and the calcium content of the ovarian extraction rat, as will be described in detail later with examples of wiping.
  • mebithiostane and epithiostanol according to the present invention significantly increased the femoral calcium content of the sciatic nerve transection rat. It is clear that the mepithiostan and epichostanol according to the present invention have a bone formation promoting action.
  • mebitiostan and ebitiostanol according to the present invention has an action to promote bone formation.
  • the mebithiostane and evithiostanol according to the present invention can therefore also be used as bone formation promoters.
  • the mebithiostane and ebithiosanol according to the present invention are used as a therapeutic agent for osteoporosis or an agent for promoting bone formation, they may be used alone or in combination.
  • mepithiostan and epithiostanol according to the present invention are administered as a medicament, they may be used as such or in a pharmaceutically acceptable non-toxic and inert carrier, for example, from 0.1% to 99.5%, preferably from 9% to 99.5%. , 0.5% to 90% as a pharmaceutical composition.
  • a pharmaceutically acceptable non-toxic and inert carrier for example, from 0.1% to 99.5%, preferably from 9% to 99.5%. , 0.5% to 90% as a pharmaceutical composition.
  • the therapeutic agent for osteoporosis is preferably administered in a unit dosage form.
  • the therapeutic agent for osteoporosis of the present invention can be administered intravenously, orally, intravenously, topically (eg, eye drops, eye drops) or rectally. Needless to say, it is administered in a dosage form suitable for these administration methods. Oral administration is particularly preferred.
  • the dosage as a treatment for osteoporosis depends on the patient's condition, such as age and weight. It is desirable to set the dose taking into account the route of administration, the nature and degree of the disease, etc., but usually, the amount of the active ingredient of the present invention for an adult is 1 to 50 per day orally when administered orally. A range of m humans is preferred, preferably in the range of 5 to 20 mg. In some cases, lower doses may be sufficient and vice versa. It can also be administered in divided doses 2 to 4 times daily.
  • Oral administration is preferably carried out in solid or liquid dosage units.
  • powders, powders, tablets, dragees, capsules, granules, suspensions, solutions, syrups, drops, sublingual tablets It can be performed by other dosage forms.
  • Powders are prepared by comminuting the active substance to an appropriate degree.
  • Powders are prepared by comminuting the active substance to a suitable finely divided form and then mixing with a similarly comminuted pharmaceutical carrier, for example, edible carbohydrates such as mannitol, and the like. If necessary, flavoring agents, preservatives, aromatics, coloring agents, spices and other substances may be mixed.
  • Capsules are produced by first filling a powdered powder, powder or tablet obtained as described above into granules and into a capsule made of forceps such as a gelatin capsule.
  • Lubricants and fluidizers such as colloidal silica, talc, magnesium stearate, calcium stearate, and solid polyethylene glycol, can be mixed with the powdered material and then filled. it can.
  • disintegrants and solubilizers such as carboxymethylcellulose, carboxymethylcellulose calcium, low-substituted hydroxypropyl cellulose, croscarmellose sodium, carboquin starch sodium, calcium carbonate, sodium carbonate, etc. It can improve the effectiveness of the medicine when taken.
  • fine powder of this product is mixed with vegetable oil, polyethylene glycol, glycerin It can be suspended and dispersed in a surfactant and wrapped in a gelatin sheet to give a capsule.
  • Tablets are made by preparing a powder mixture, granulating or slugging, adding a disintegrant or lubricant and compressing.
  • the powder mixture may be obtained by mixing the appropriately powdered substance with the above-mentioned diluents and bases and, if necessary, binding agents (eg, carboxymethylcellulose sodium, hydroxypropyl senorelose, methylsenorelose, Droxypropyl methylcellulose, gelatin, polyvinylpyrrolidone, polyvinyl alcohol, etc.), dissolution retarder (eg, paraffin, wax, hydrogenated castor oil, etc.), reabsorbent (eg, quaternary salt, etc.) and adsorbent ( For example, bentonite, kaolin, dicalcium phosphate, etc.) may be used in combination.
  • binding agents eg, carboxymethylcellulose sodium, hydroxypropyl senorelose, methylsenorelose, Droxypropyl methylcellulose, gelatin, polyvinylpyrrolidone, polyvinyl alcohol, etc.
  • dissolution retarder eg, paraffin, wax, hydrogen
  • the powder mixture can be first moistened with a binder such as syrup, starch paste, gum arabic, cellulose fibrous or polymeric solution, and then forced through a sieve to form granules.
  • a binder such as syrup, starch paste, gum arabic, cellulose fibrous or polymeric solution
  • the granules thus produced can be prevented from adhering to each other by adding stearic acid, stearates, talc, mineral oil and the like as lubricants.
  • the lubricated mixture is then tableted.
  • the uncoated tablets thus produced can be coated with a film coating and sugar coating.
  • the drug may be directly tableted after mixing with a fluid inert carrier without going through the steps of granulation and slag formation as described above.
  • a transparent or translucent protective coating composed of a tightly closed shell of shellac, a coating of sugar or a polymer material, and a polishing coating composed of wax can also be used.
  • Other oral dosage forms such as solutions, syrups, elixirs and the like can also be in dosage unit form so that the given quantity contains a certain amount of vegetable.
  • Syrups are prepared by dissolving the compound in a suitable aqueous flavor solution, and elixirs are prepared through the use of a non-toxic alcoholic carrier.
  • Suspensions are formulated by dispersing the compound in a non-toxic carrier.
  • Solubilizers and emulsifiers eg, ethoxylated isostearyl alcohol ⁇ ⁇ , boroxyethylene sorbitol esters
  • preservatives eg, ⁇ oil, saccharin
  • flavor enhancers eg, ⁇ oil, saccharin
  • dosage unit formulations for oral administration may be microcapsulated.
  • the formulation can also provide extended duration of action and sustained release by coating or embedding in polymers, waxes, etc.
  • Administration into tissues can be carried out using liquid dosage unit forms for subcutaneous, intramuscular or intravenous injection, such as solutions and suspensions.
  • a fixed amount of the compound is suspended or dissolved in a non-toxic liquid carrier suitable for the purpose of injection, such as an aqueous or oily medium, and the suspension or solution is sterilized. It is manufactured by Alternatively, an aliquot of the compound may be placed in a vial, and then the vial and its contents sterilized and sealed.
  • Spare vials or carriers may be provided with the powdered or lyophilized active component for dissolving or mixing immediately prior to administration.
  • Non-toxic salts or salt solutions may be added to make the injection solution isotonic.
  • stabilizers, preservatives [J, emulsifiers, etc.] can be used in combination.
  • the animals used were Jc 1 -Wister and Jc 1 -Sprague Dawley (SD) 4- and 7-month-old female rats (Clea Japan) and were fed (commercially available). Products, CE-2, manufactured by Nippon Clea) and drinking water were allowed to be consumed freely.
  • test drugs mepithiostan and epichostanol were dissolved in sesame oil.
  • the comparison drug testosterone 'propionic acid (Tokyo Kasei Kogyo Co., Ltd.) is broken down into sesame oil, and oxymetholone (Syntex Pharma cuetica 1s Internation al Ltd.) is suspended in sesame oil. did.
  • Vitamin K 2 is a commercial product (10 mg Zm 1; manufactured by Eisai Co., Ltd.) as it is, and 1 is 25.
  • Main Pichiosutan, Okishime preparative port emissions and vitamin K f is once daily, continuous oral administration, S. Torajio one route 1 7 3 once a day, and continuous subcutaneous injection. Eviostanol and testosterone 'propionic acid were injected subcutaneously three times a week every other day, and 1 ⁇ , 25 (OH) 1 DS was orally administered three times a week every other day. The dose volume of each drug was 1 m1Zkg.
  • the animals were intraperitoneally administered with pentobarbital'sodium (Somnopentyl; Pitman Moore), and bilateral ovaries were removed from the back under anesthesia.
  • test drug or comparator was administered once a day, 60 days continuously, or three times a week every other day for 9 weeks after 1 month .
  • test drug or the comparative drug is administered once daily for 3 months after ovariectomy, and after 3 months when the amount of calcium in the femur has decreased. Administered for 13 weeks. The day after the final administration, the femur was excised, the muscle tissue was removed, and the wet weight was measured.
  • the bilateral ovaries of a 7-month-old rat were excised, and the right sciatic nerve was excised about 5 to 10 mm at the center of the femur.
  • the test drug and control drug were administered once a day from the operation day for 90 consecutive days.
  • Femur black port Holm 'ethanol (2: 1) solution degreasing (3 hours, 2 times) after dried for 24 hours at 1 1 0 e C.
  • the dried femur was ashed in an electric furnace (250 ° C. 400 ° C, 600 ° C, 1 hour each, 800 ° C for 5 hours), weighed, and then 1 N hydrochloric acid was dissolved.
  • the amount of force on the femur was colorimetrically determined using a calcium determination reagent (Calcium C-Test Co .; manufactured by Wako Pure Chemical Industries, Ltd.). Knot
  • Table 1 shows the results of oral administration of mebitiostan and oximetron for 60 days after oral ovariectomy of SD rats (body weight: 296-356 g) for 1 month.
  • Mepithiostan significantly inhibited the decrease in calcified femoral bone mass and lucidum content due to ovariectomy at doses of 0.2 mg / kg and 1 mg / kg / day.
  • oximetron was also significantly suppressed at 10 and 50 mg / k days.
  • W istar system rats (body weight 228 ⁇ 273 g) E-bi Chio stanol after ovariectomy 1 month, testosterone, Burobion acid and 1 ⁇ , 2 5 (OH) 2 D 3 three times a week, when administered for 9 weeks Table 2 shows the results. Both drugs significantly reduced the decrease in ash weight and potash content of the femur due to ovariectomy.
  • Mevithiostan significantly increased the femoral calcium content in the ovariectomized and sciatic nerve transection control group at a dose of 1 mg / k day.
  • estradiol-1 ⁇ (1 O xi gZkg / day) also showed a significant increase, similar to mepithiostan.
  • a solution prepared by adding mepithiostan to a solution prepared by dissolving ethyl ethyl paraoxybenzoate, propyl paraoxybenzoate, and boroxy hydrogenated castor oil in McGoal 400 was filled into a soft capsule by a conventional method to prepare capsules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un remède contre l'ostéoporose et un accélérateur d'ostéogénèse contenant du mépitiostane ou de l'épitiostanol comme ingrédient actif. Ce remède a un excellent effet thérapeutique dépassant celui de médicaments connus.
PCT/JP1995/000425 1994-02-02 1995-03-15 Remede contre l'osteoporose et accelerateur d'osteogenese WO1996028166A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP6031798A JPH07215878A (ja) 1994-02-02 1994-02-02 骨粗そう症治療剤及び骨形成促進剤
PCT/JP1995/000425 WO1996028166A1 (fr) 1994-02-02 1995-03-15 Remede contre l'osteoporose et accelerateur d'osteogenese

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6031798A JPH07215878A (ja) 1994-02-02 1994-02-02 骨粗そう症治療剤及び骨形成促進剤
PCT/JP1995/000425 WO1996028166A1 (fr) 1994-02-02 1995-03-15 Remede contre l'osteoporose et accelerateur d'osteogenese

Publications (1)

Publication Number Publication Date
WO1996028166A1 true WO1996028166A1 (fr) 1996-09-19

Family

ID=26370311

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP1995/000425 WO1996028166A1 (fr) 1994-02-02 1995-03-15 Remede contre l'osteoporose et accelerateur d'osteogenese

Country Status (1)

Country Link
WO (1) WO1996028166A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352795A (ja) * 1991-01-22 1992-12-07 Merck & Co Inc 新規な骨作用剤

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04352795A (ja) * 1991-01-22 1992-12-07 Merck & Co Inc 新規な骨作用剤

Similar Documents

Publication Publication Date Title
JP2525478B2 (ja) 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤
KR100805648B1 (ko) 복합 에스트로겐 및 메드록시프로게스테론 아세테이트와의 배합물을 사용한 호르몬 보충요법
EP0329708B1 (fr) Supplement de calcium liquide obtenu a partir de melanges instantanement solubles d'un compose de calcium et d'acide citrique
HU230162B1 (hu) Fulvesztrantot tartalmazó gyógyászati készítmény
ZA200600038B (en) Pharmaceutical composition and method for alleviating side effects of estrogen replacement therapy
CN1162096C (zh) 柠檬酸钙钾组合物和生产方法
WO2010008976A2 (fr) Compléments combinés de calcium, magnésium et vitamine d
JPH0692847A (ja) 骨粗鬆症治療剤
US6854468B2 (en) Treatment of subnormal bone mineral density
KR20030090673A (ko) 에스트로겐 대체 요법
JP2001515486A (ja) ビタミンｄ３及びトリカルシウムフォスフェートを含有する安定な固形製剤
JP3459932B2 (ja) 抗骨粗鬆症組成物
US6441041B1 (en) (-)-hydroxycitric acid for the prevention of osteoporosis
JP3712732B2 (ja) 骨形成の疾患に作用する剤
JPH093092A (ja) 骨損失抑制用医薬製剤
WO1996028166A1 (fr) Remede contre l'osteoporose et accelerateur d'osteogenese
WO2009087652A2 (fr) Compositions pharmaceutiques de calcitriol et de suppléments minéraux
JPH07215878A (ja) 骨粗そう症治療剤及び骨形成促進剤
JP2003055238A (ja) 抗骨粗鬆活性を有する組成物
AU692155B2 (en) Method and composition for treatment of osteoporosis
WO2007046123A2 (fr) Composition contenant les vitamines k et d destinee a prevenir et a traiter l'osteoporose
JP3947244B2 (ja) 消化性潰瘍治療用製剤
JP2616845B2 (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
KR20190098638A (ko) 비스포스포네이트 및 콜레칼시페롤을 함유하는 경구용 에멀젼 조성물 및 그 제조방법
JP4896531B2 (ja) 血中ＣｏＱ１０量を増加させる医薬組成物

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1995912410

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995912410

Country of ref document: EP

122 Ep: pct application non-entry in european phase